HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Gert Van Assche Selected Research

Inflammatory Bowel Diseases (Inflammatory Bowel Disease)

12/2015Anti-Tumor Necrosis Factor Therapy Restores Peripheral Blood B-cell Subsets and CD40 Expression in Inflammatory Bowel Diseases.
12/2015Serum Neutrophil Gelatinase B-associated Lipocalin and Matrix Metalloproteinase-9 Complex as a Surrogate Marker for Mucosal Healing in Patients with Crohn's Disease.
11/2015Strong Upregulation of AIM2 and IFI16 Inflammasomes in the Mucosa of Patients with Active Inflammatory Bowel Disease.
10/2015Restoration of Foxp3+ Regulatory T-cell Subsets and Foxp3- Type 1 Regulatory-like T Cells in Inflammatory Bowel Diseases During Anti-tumor Necrosis Factor Therapy.
6/2015Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
9/2014Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases.
6/2014Tuberculosis infection following anti-TNF therapy in inflammatory bowel disease, despite negative screening.
2/2014Infliximab restores the dysfunctional matrix remodeling protein and growth factor gene expression in patients with inflammatory bowel disease.
1/2014Targeting TNF-α for the treatment of inflammatory bowel disease.
12/2013Intravenous iron for the treatment of iron deficiency in IBD: the pendulum is swinging.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Gert Van Assche Research Topics

Disease

64Crohn Disease (Crohn's Disease)
12/2015 - 08/2002
44Ulcerative Colitis
12/2015 - 10/2002
38Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
12/2015 - 07/2004
23Inflammation
09/2014 - 08/2002
10Colitis
01/2015 - 09/2002
6Infection
01/2015 - 07/2006
5Rheumatoid Arthritis
01/2013 - 06/2005
4Necrosis
09/2014 - 07/2006
3Fibrosis (Cirrhosis)
01/2013 - 02/2003
3Fistula
02/2010 - 02/2003
2Tuberculosis (Tuberculoses)
06/2014 - 09/2011
2Ulcer
01/2014 - 10/2004
2Nausea
12/2013 - 02/2003
2Proctitis
07/2013 - 10/2002
2Pouchitis
02/2010 - 06/2008
2Pathologic Constriction (Stenosis)
09/2008 - 01/2004
2Ileitis
06/2008 - 09/2002
2Acute-Phase Reaction
12/2005 - 09/2004
1Immune Reconstitution Inflammatory Syndrome
06/2014
1Pain (Aches)
12/2013
1Abdominal Pain (Pain, Abdominal)
12/2013
1Iron-Deficiency Anemia (Anemia, Iron Deficiency)
12/2013
1Irritable Bowel Syndrome (Syndrome, Irritable Bowel)
09/2013
1Psoriasis (Pustulosis Palmaris et Plantaris)
01/2013
1Melanoma (Melanoma, Malignant)
01/2013
1Skin Neoplasms (Skin Cancer)
01/2013
1Neoplasms (Cancer)
01/2013
1Portal Hypertension
11/2012
1Granuloma
02/2012
1Lymphoma (Lymphomas)
09/2011
1Demyelinating Diseases (Demyelinating Disease)
09/2011
1Pneumonia (Pneumonitis)
09/2011
1T-Cell Lymphoma (Lymphoma, T Cell)
12/2010
1Non-Hodgkin Lymphoma (Lymphosarcoma)
12/2010

Drug/Important Bio-Agent (IBA)

51infliximab (Remicade)FDA Link
12/2015 - 08/2002
26Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
12/2015 - 08/2002
10adalimumab (Humira)FDA Link
03/2013 - 07/2005
10AntibodiesIBA
12/2009 - 08/2002
9Phenobarbital (Luminal)FDA Link
02/2010 - 05/2004
8Azathioprine (Imuran)FDA LinkGeneric
08/2015 - 02/2003
8Cyclosporine (Ciclosporin)FDA LinkGeneric
01/2013 - 02/2003
7SteroidsIBA
12/2012 - 02/2003
6Adrenal Cortex Hormones (Corticosteroids)IBA
01/2014 - 02/2007
5Biological Markers (Surrogate Marker)IBA
12/2015 - 12/2005
5natalizumab (Tysabri)FDA Link
09/2011 - 07/2005
5C-Reactive ProteinIBA
10/2010 - 09/2002
4Immunologic Factors (Immunomodulators)IBA
03/2015 - 02/2009
4Immunoglobulin G (IgG)IBA
12/2007 - 06/2005
3Immunosuppressive Agents (Immunosuppressants)IBA
09/2014 - 09/2008
3Leukocyte L1 Antigen Complex (Calgranulin)IBA
09/2013 - 09/2004
3purineIBA
09/2012 - 07/2009
3Interferon-gamma (Interferon, gamma)IBA
03/2007 - 07/2005
3CytokinesIBA
03/2007 - 07/2004
2LipocalinsIBA
12/2015 - 07/2014
2Matrix Metalloproteinase 9 (Gelatinase B)IBA
12/2015 - 07/2014
2Beclomethasone (Beclometasone)FDA Link
06/2015 - 05/2015
2Prednisone (Sone)FDA LinkGeneric
06/2015 - 05/2015
2Carbon MonoxideIBA
03/2015 - 12/2013
2Anti-Bacterial Agents (Antibiotics)IBA
01/2015 - 02/2010
2Messenger RNA (mRNA)IBA
01/2014 - 03/2007
2IronIBA
12/2013 - 12/2007
2Mesalamine (Mesalazine)FDA LinkGeneric
06/2013 - 10/2002
2Methotrexate (Mexate)FDA LinkGeneric
01/2013 - 09/2007
2ChemokinesIBA
04/2011 - 07/2004
2visilizumabIBA
11/2010 - 11/2007
2Indomethacin (Indometacin)FDA LinkGeneric
08/2010 - 07/2005
2Immunoglobulins (Immunoglobulin)IBA
04/2009 - 05/2004
2PeptidesIBA
01/2009 - 10/2007
2CDP870FDA Link
01/2009 - 12/2007
2Monoclonal AntibodiesIBA
09/2008 - 06/2005
2OxazoloneIBA
03/2007 - 07/2004
2Interleukin-12 (IL 12)IBA
01/2006 - 07/2005
2Interleukin-6 (Interleukin 6)IBA
12/2005 - 09/2004
1InflammasomesIBA
11/2015
1corrigendumIBA
06/2015
1Metalloproteases (Metalloproteinases)IBA
02/2014
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
02/2014
1ThrombospondinsIBA
02/2014
1Matrix MetalloproteinasesIBA
02/2014
1MicroRNAs (MicroRNA)IBA
01/2014
14-amino-4'-hydroxylaminodiphenylsulfone (HADS)IBA
12/2013
1LactoferrinIBA
09/2013
1vedolizumabIBA
08/2013
1XENP 1595IBA
02/2013
1Dextrans (Dextran)FDA Link
01/2013
1Interleukin-15 Receptors (Interleukin 15 Receptor)IBA
01/2013
1Extracellular Matrix ProteinsIBA
01/2013
1TenascinIBA
01/2013
1SodiumIBA
01/2013
1Interleukin-15 (Interleukin 15)IBA
01/2013
1SmokeIBA
02/2012
1Cell Adhesion MoleculesIBA
04/2011
1Cadherins (E-Cadherin)IBA
04/2011
1Interleukin-8 (Interleukin 8)IBA
04/2011
1Chemokine ReceptorsIBA
04/2011
1Primary sclerosing cholangitisIBA
12/2010

Therapy/Procedure

10Colectomy
01/2015 - 09/2004
7Biological Therapy
07/2013 - 07/2006
1Colostomy
07/2013
1Transplantation (Transplant Recipients)
11/2012